Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France

This study has been completed.

First Received: May 19, 2008 Last Updated: November 17, 2008 History of Changes

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00681837

Purpose

The purpose of this study is to assess prevalence of gastrooesophageal reflux during childhood and teenage years in France and to describe patients'symptoms and gastrooesophageal reflux management

Condition
Gastroesophageal Reflux

Study Type:	Observational
Study Design:	Cohort, Cross-Sectional
Official Title:	Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France

Resource links provided by NLM:

MedlinePlus related topics: GERD

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

assess prevalence of gastrooesophageal reflux during childhood and teenage years in France, particularly 0-1 year-old prevalence and 1-11 year-old prevalence [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

describe patients'symptoms and gastrooesophageal reflux management [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	2500
Study Start Date:	May 2008
Study Completion Date:	September 2008

Groups/Cohorts
1 children from 0 to 17 years old

Eligibility

Ages Eligible for Study:	up to 17 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

children recruited by both GPs and paediatricians

Criteria

Inclusion Criteria:

children from 0 to 17years old seen in consultation

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00681837

Show 25 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Study Chair:	Frédéric GOTTRAND	CHRU Lille - France
Principal Investigator:	Geneviève BONNELYE	TNS Healthcare 92120 Montrouge - France

More Information

No publications provided

Responsible Party:	AstraZeneca ( Paula Fernstrom )
Study ID Numbers:	NIS-GFR-DUM-2008/1
Study First Received:	May 19, 2008
Last Updated:	November 17, 2008
ClinicalTrials.gov Identifier:	NCT00681837 History of Changes
Health Authority:	France: Haute Autorité de Santé Transparency Commission

Keywords provided by AstraZeneca:

gastroesophageal reflux
prevalence
childhood
France

Study placed in the following topic categories:

Deglutition Disorders
Esophageal Motility Disorders
Digestive System Diseases
Esophageal Disorder

Gastrointestinal Diseases
Esophageal Diseases
Gastroesophageal Reflux

Additional relevant MeSH terms:

Deglutition Disorders
Esophageal Motility Disorders
Digestive System Diseases

Gastrointestinal Diseases
Esophageal Diseases
Gastroesophageal Reflux

ClinicalTrials.gov processed this record on July 02, 2009